Mometason Aristo Heuschnupfenspray (Mometasone Furoate Ph. Eur.)

Mometasone furoate, the active ingredient in Mometason Aristo Heuschnupfenspray, is a glucocorticoid presented as a nasal spray for nasal use. It treats allergic rhinitis and seasonal nasal allergy in adults and children.

GNH USA supplies Mometason Aristo Heuschnupfenspray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray is used to manage inflammatory conditions of the nasal passages associated with allergic rhinitis.

Allergic rhinitis: reduces nasal congestion, itching, and sneezing. Seasonal nasal allergy: provides symptom relief during pollen or other seasonal allergen exposure. Hay fever: controls nasal symptoms during hay‑fever episodes.

Adverse reactions may occur with nasal administration of mometasone furoate.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleed). - Throat irritation or dryness. - Cough. - Altered taste or bitter taste.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Vision changes or increased intra‑ocular pressure. - Systemic corticosteroid effects such as adrenal suppression. - Fungal infection of the nasal passages. - Persistent nasal dryness leading to crusting.

Before using Mometason Aristo Heuschnupfenspray, consider the following safety measures.

Pregnancy: consult a healthcare provider before use. Breastfeeding: discuss potential risks with a physician. Nasal infection: avoid use if an active infection of the nasal passages is present. Long‑term therapy: monitor for signs of nasal mucosal atrophy or septal perforation. Pediatric use: follow pediatric dosing guidance and monitor growth. Store at room temperature: keep in the original container, protect from moisture and light.

Mometasone furoate nasal spray may interact with other medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise local drug exposure. - Live nasal vaccines: potential reduction in vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., itraconazole): may increase mometasone levels. - Ritonavir or other protease inhibitors: may elevate exposure. - St. John's wort or other CYP3A4 inducers: may reduce therapeutic effect.